Pathologic complete response and survival in HER2-low and HER2-zero early breast cancer treated with neoadjuvant chemotherapy

BACKGROUND: Breast cancers without HER2 amplification but still expressing this membrane protein constitute a new entity called HER2-low tumors. It is important to characterize them in terms of sensitivity to treatment and prognosis. PATIENTS AND METHODS: To investigate chemosensitivity and long-ter...

Descripción completa

Detalles Bibliográficos
Autores principales: Ilie, Silvia Mihaela, Briot, Nathalie, Constantin, Guillaume, Roussot, Nicolas, Ilie, Alis, Bergeron, Anthony, Arnould, Laurent, Beltjens, Françoise, Desmoulin, Isabelle, Mayeur, Didier, Kaderbhai, Courèche, Hennequin, Audrey, Jankowski, Clémentine, Padeano, Marie Martine, Costaz, Helène, Amet, Alix, Coutant, Charles, Coudert, Bruno, Bertaut, Aurélie, Ladoire, Sylvain
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Nature Singapore 2023
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10587331/
https://www.ncbi.nlm.nih.gov/pubmed/37561255
http://dx.doi.org/10.1007/s12282-023-01490-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10587331/
https://www.ncbi.nlm.nih.gov/pubmed/37561255
http://dx.doi.org/10.1007/s12282-023-01490-1

Ejemplares similares